Global Orphan Drugs 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI04250476

Publication Date:

April 17, 2025

Pages:

103

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Orphan Drugs market size is predicted to grow from US$ 177570 million in 2025 to US$ 318510 million in 2031; it is expected to grow at a CAGR of 10.2% from 2025 to 2031.
An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.
Bristol-Myers Squibb is one of the most important global key players of orphan drugs, holds a share of about 10%, other key players include Roche and Novartis, etc. North America is the largest market, occupied for about 40 percent, followed by Asia-Pacific. In terms of type, oncology is the largest segment, with a share of over 60%, and in terms of application, the adult segment holds a share of about 40 percent.
The 鈥淥rphan Drugs Industry Forecast鈥� looks at past sales and reviews total world Orphan Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Orphan Drugs sales for 2025 through 2031. With Orphan Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orphan Drugs industry.
This Insight Report provides a comprehensive analysis of the global Orphan Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Orphan Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Orphan Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orphan Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orphan Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Orphan Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Oncology
Pulmonary
Neurology
Hematology
Endocrinology
Cardio-vascular
Metabolic Disorders
Others
Segmentation by Application:
Baby and Child
Teenager
Adult
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bristol-Myers Squibb
Roche
Novartis
Johnson & Johnson
Pfizer
Amgen
Sanofi
AstraZeneca
Takeda
Vertex Pharmaceuticals
AbbVie
Biogen
Eli Lilly

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Orphan Drugs 麻豆原创 Size (2020-2031)
2.1.2 Orphan Drugs 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Orphan Drugs by Country/Region (2020, 2024 & 2031)
2.2 Orphan Drugs Segment by Type
2.2.1 Oncology
2.2.2 Pulmonary
2.2.3 Neurology
2.2.4 Hematology
2.2.5 Endocrinology
2.2.6 Cardio-vascular
2.2.7 Metabolic Disorders
2.2.8 Others
2.3 Orphan Drugs 麻豆原创 Size by Type
2.3.1 Orphan Drugs 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Orphan Drugs 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Orphan Drugs Segment by Application
2.4.1 Baby and Child
2.4.2 Teenager
2.4.3 Adult
2.4.4 Other
2.5 Orphan Drugs 麻豆原创 Size by Application
2.5.1 Orphan Drugs 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Orphan Drugs 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Orphan Drugs 麻豆原创 Size by Player
3.1 Orphan Drugs 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Orphan Drugs Revenue by Player (2020-2025)
3.1.2 Global Orphan Drugs Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Orphan Drugs Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Orphan Drugs by Region
4.1 Orphan Drugs 麻豆原创 Size by Region (2020-2025)
4.2 Global Orphan Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Orphan Drugs 麻豆原创 Size Growth (2020-2025)
4.4 APAC Orphan Drugs 麻豆原创 Size Growth (2020-2025)
4.5 Europe Orphan Drugs 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Orphan Drugs 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Orphan Drugs 麻豆原创 Size by Country (2020-2025)
5.2 Americas Orphan Drugs 麻豆原创 Size by Type (2020-2025)
5.3 Americas Orphan Drugs 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Orphan Drugs 麻豆原创 Size by Region (2020-2025)
6.2 APAC Orphan Drugs 麻豆原创 Size by Type (2020-2025)
6.3 APAC Orphan Drugs 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Orphan Drugs 麻豆原创 Size by Country (2020-2025)
7.2 Europe Orphan Drugs 麻豆原创 Size by Type (2020-2025)
7.3 Europe Orphan Drugs 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Orphan Drugs by Region (2020-2025)
8.2 Middle East & Africa Orphan Drugs 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Orphan Drugs 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Orphan Drugs 麻豆原创 Forecast
10.1 Global Orphan Drugs Forecast by Region (2026-2031)
10.1.1 Global Orphan Drugs Forecast by Region (2026-2031)
10.1.2 Americas Orphan Drugs Forecast
10.1.3 APAC Orphan Drugs Forecast
10.1.4 Europe Orphan Drugs Forecast
10.1.5 Middle East & Africa Orphan Drugs Forecast
10.2 Americas Orphan Drugs Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Orphan Drugs Forecast
10.2.2 Canada 麻豆原创 Orphan Drugs Forecast
10.2.3 Mexico 麻豆原创 Orphan Drugs Forecast
10.2.4 Brazil 麻豆原创 Orphan Drugs Forecast
10.3 APAC Orphan Drugs Forecast by Region (2026-2031)
10.3.1 China Orphan Drugs 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Orphan Drugs Forecast
10.3.3 Korea 麻豆原创 Orphan Drugs Forecast
10.3.4 Southeast Asia 麻豆原创 Orphan Drugs Forecast
10.3.5 India 麻豆原创 Orphan Drugs Forecast
10.3.6 Australia 麻豆原创 Orphan Drugs Forecast
10.4 Europe Orphan Drugs Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Orphan Drugs Forecast
10.4.2 France 麻豆原创 Orphan Drugs Forecast
10.4.3 UK 麻豆原创 Orphan Drugs Forecast
10.4.4 Italy 麻豆原创 Orphan Drugs Forecast
10.4.5 Russia 麻豆原创 Orphan Drugs Forecast
10.5 Middle East & Africa Orphan Drugs Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Orphan Drugs Forecast
10.5.2 South Africa 麻豆原创 Orphan Drugs Forecast
10.5.3 Israel 麻豆原创 Orphan Drugs Forecast
10.5.4 Turkey 麻豆原创 Orphan Drugs Forecast
10.6 Global Orphan Drugs Forecast by Type (2026-2031)
10.7 Global Orphan Drugs Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Orphan Drugs Forecast
11 Key Players Analysis
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Orphan Drugs Product Offered
11.1.3 Bristol-Myers Squibb Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Bristol-Myers Squibb Main Business Overview
11.1.5 Bristol-Myers Squibb Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Orphan Drugs Product Offered
11.2.3 Roche Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Novartis
11.3.1 Novartis Company Information
11.3.2 Novartis Orphan Drugs Product Offered
11.3.3 Novartis Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Novartis Main Business Overview
11.3.5 Novartis Latest Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information
11.4.2 Johnson & Johnson Orphan Drugs Product Offered
11.4.3 Johnson & Johnson Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Johnson & Johnson Main Business Overview
11.4.5 Johnson & Johnson Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Orphan Drugs Product Offered
11.5.3 Pfizer Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 Amgen
11.6.1 Amgen Company Information
11.6.2 Amgen Orphan Drugs Product Offered
11.6.3 Amgen Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Amgen Main Business Overview
11.6.5 Amgen Latest Developments
11.7 Sanofi
11.7.1 Sanofi Company Information
11.7.2 Sanofi Orphan Drugs Product Offered
11.7.3 Sanofi Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Sanofi Main Business Overview
11.7.5 Sanofi Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Orphan Drugs Product Offered
11.8.3 AstraZeneca Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 Takeda
11.9.1 Takeda Company Information
11.9.2 Takeda Orphan Drugs Product Offered
11.9.3 Takeda Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Takeda Main Business Overview
11.9.5 Takeda Latest Developments
11.10 Vertex Pharmaceuticals
11.10.1 Vertex Pharmaceuticals Company Information
11.10.2 Vertex Pharmaceuticals Orphan Drugs Product Offered
11.10.3 Vertex Pharmaceuticals Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Vertex Pharmaceuticals Main Business Overview
11.10.5 Vertex Pharmaceuticals Latest Developments
11.11 AbbVie
11.11.1 AbbVie Company Information
11.11.2 AbbVie Orphan Drugs Product Offered
11.11.3 AbbVie Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 AbbVie Main Business Overview
11.11.5 AbbVie Latest Developments
11.12 Biogen
11.12.1 Biogen Company Information
11.12.2 Biogen Orphan Drugs Product Offered
11.12.3 Biogen Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Biogen Main Business Overview
11.12.5 Biogen Latest Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Orphan Drugs Product Offered
11.13.3 Eli Lilly Orphan Drugs Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Eli Lilly Main Business Overview
11.13.5 Eli Lilly Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.